Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 4/20 | 0.69 |
| ▸ | NPY2R | P49146 | 1/20 | 0.69 |
| ▸ | NPY4R | P50391 | 1/20 | 0.69 |
| ▸ | MC4R | P32245 | 2/20 | 0.59 |
| ▸ | MC3R | P41968 | 2/20 | 0.59 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.57 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.57 |
| ▸ | C3AR1 | Q16581 | 3/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D[-Arg-2]Kyotorphan Acetate SCHEMBL31332230 | 1.00 | NPY1R (0.69) | NPY1RNPY2RNPY4RMC4RMC3R | |
| Kyotorphin SCHEMBL28292 | 1.00 | NPY1R (0.69) | NPY1RNPY2RNPY4RMC4RMC3R | |
| Kyotorphin SCHEMBL29966938 | 1.00 | NPY1R (0.69) | NPY1RNPY2RNPY4RMC4RMC3R | |
| SCHEMBL29471109 | 0.91 | MC4R (0.67) | NPY1RNPY2RNPY4RMC4RMC3R | |
| SCHEMBL29936161 | 0.89 | NPY4R (0.69) | NPY1RNPY2RNPY4RNPFFR1NPFFR2 | |
| SCHEMBL29351314 | 0.88 | MC4R (0.65) | NPY1RNPY2RNPY4RMC4RMC3R | |
| SCHEMBL29360943 | 0.88 | NPY1R (0.60) | NPY1RNPY2RNPY4RMC4RMC3R | |
| SCHEMBL29349984 | 0.85 | NPY1R (0.65) | NPY1RNPY2RNPY4RMC4RMC3R | |
| SCHEMBL29350671 | 0.85 | NPY1R (0.73) | NPY1RNPY2RNPY4RERAP2ERAP1 | |
| SCHEMBL29406227 | 0.84 | LNPEP (0.61) | NPY1RNPY2RNPY4RERAP2LNPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | claimed |
| US-20240342321-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-10-17 | — | — | US | claimed |
| US-20240100203-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-03-28 | — | — | US | claimed |
| EP-4232459-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | Provincial Health Services Authority (CA) | 2023-08-30 | — | — | EP | claimed |
| WO-2022082312-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-04-28 | — | — | WO | claimed |
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | disclosed |
| US-20250249113-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING SA (CH) | 2025-08-07 | — | — | US | disclosed |
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-31 | — | — | US | disclosed |
| WO-2025083205-A1 | DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-04-24 | — | — | WO | disclosed |
| EP-4511384-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | Provincial Health Services Authority (CA) | 2025-02-26 | — | — | EP | disclosed |
| EP-4507734-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | Debiopharm Research & Manufacturing S.A. (CH) | 2025-02-19 | — | — | EP | disclosed |
| US-20240342321-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-10-17 | — | — | US | disclosed |
| US-20240100203-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2024-03-28 | — | — | US | disclosed |
| WO-2023201435-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023198884-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2023-10-19 | — | — | WO | disclosed |
| EP-4232459-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | Provincial Health Services Authority (CA) | 2023-08-30 | — | — | EP | disclosed |
| EP-4076493-A1 | MACROCYCLIC PEPTIDES AS POTENT INHIBITORS OF K-RAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2022-10-26 | — | — | EP | disclosed |
| CN-112972701-B | Polypeptide/gene co-delivery material, preparation method and application | 天津大学 | 2022-09-23 | — | — | CN | disclosed |
| WO-2022082312-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | CXCR4, CXCL12, ACKR3 | NPY1R 129/4885NPY2R 168/4885NPY4R 171/4885 |
| US-20240100203-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | CXCR4, CXCL12, CXCR2 | NPY1R 187/4885NPY2R 194/4885NPY4R 279/4885 |
| US-20240342321-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | CXCR4, CXCL12, CXCR2 | NPY1R 187/4885NPY2R 194/4885NPY4R 279/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | NPY1R 68/4885NPY2R 61/4885NPY4R 154/4885 |
| US-20250249113-A1 | LIGAND-DRUG-CONJUGATES WITH IMPROVED PHARMACOKINETIC AND DRUG RELEASE PROPERTIES | FCER2, FCGR2A, FCGR1A | NPY1R 1775/4885NPY2R 2140/4885NPY4R 2161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.